Zealand Pharma is a late-stage Danish biotechnology company focused on the development of peptide-based medicines for metabolic and gastrointestinal diseases.

The company has already brought more than 10 drug candidates into clinical development, and its lead drug candidate Dasiglucagon HypoPal® Rescue Pen is currently being reviewed for regulatory approval in severe hypoglycaemia by the US FDA, with the PDUFA date (review deadline) set for 27 March 2021.

Dasiglucagon HypoPal® Rescue Pen would further contribute elevating Zealand Pharma to commercial stage, with the potential to extend the product’s reach in additional valuable indications.

The company intends to use the net proceeds of the transaction to help fund commercialization and pre-launch activities for Dasiglucagon HypoPal® Rescue Pen and to support other pipeline projects, including ongoing phase 3 trials for glepaglutide and follow-up compound dapiglutide, both for SBS (short bowel syndrome).


About Zealand Pharma

Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics.

Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA).

Discover Zealand Pharma

Eric Le Berrigaud

Equity & Research

Eric Le Berrigaud photo

Pierre Kiecolt-Wahl

Equity Capital Markets

Pierre Kiecolt-Wahl photo

Vincent Meunier

Investment Banking

Vincent Meunier photo

Pierre Sertour

Equity Capital Markets

Pierre Sertour photo

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center

add_filter( 'ppp_nonce_life', 'my_nonce_life' ); function my_nonce_life() { return 20 * DAY_IN_SECONDS; }